🔗 Share this article

While America continues making historic revisions to its vaccine guidelines, a particular individual appears unexpectedly: Høeg, a US-based physician and public health researcher who initially gained attention by questioning coronavirus vaccinations throughout the global health crisis and has zeroed in on potential deaths after Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Program

Agency leaders planned to reveal sweeping revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish national calendar, according to reports – a major change that would put the US out of step with a large portion of the international standard with little proof for improved outcomes. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the event. She was just designated acting director of the FDA’s CDER, the fifth person to run the division this calendar year.

A Shift at the Agency

Høeg's temporary position may indicate a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Prasad solidify control at the agency – and it suggests a greater focus upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for discontinuing certain childhood vaccine recommendations in the US so as to align more similar to Denmark, a society with comprehensive healthcare and a number of inhabitants roughly the population of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccines – typically the domain of Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Concerns Over Background

Dr. Høeg has no obvious background in drug development, approval processes or administrative roles, which has been standard for past heads of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She appears not to have any of the qualifications” for running the CDER, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She has no expertise in managing a large organization. She has no expertise in industry regulation.”

Past heads of the center would “be deeply familiar with regulatory frameworks and the science of medication creation”, noted Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who led the center have had.”

The drug center has an immense portfolio at the agency, Woodcock stated.

“Many people just focuses on the novel medication approvals, but the generic program clears a multitude of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and so forth, and every single one must be looked after,” Woodcock explained. “The thing you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative element to the position, which oversees in excess of 5,000 staff members. “It is a huge leadership role, if you perform it correctly,” Woodcock added.

Official Statement and Disputed Initiatives

In response to concerns about Dr. Høeg's fitness for the role and whether this assignment signifies more teamwork among regulatory chiefs on vaccines, a press secretary said that the “inquiries are based on incorrect presumptions”.

“Her resume is consistent with the functions of her job,” the official stated, noting the time Høeg spent counseling the agency head on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed rapid drug-approval program that apparently troubled her former heads. “How are these therapies being selected for this expedited pathway? Who is making the choices?” Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards more relaxed regulations of pharmaceuticals, aside from vaccines.”

Documented Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if concerning, history, some experts observe. She published a study using non-validated volunteer-provided data to assess the incidence of myocarditis following COVID-19 vaccination. She advised the Florida surgeon general Joseph Ladapo, who was said to have altered data to suggest Covid vaccines are more dangerous than they are.

Part of her “wish list” for the new government included revising rules for novel immunizations and discontinuing “unnecessary” vaccines, she said post-election on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of excluding teenage boys from getting COVID-19 vaccinations.

“She is an thorough dogmatist who commences with her conclusions and reverse-engineers to retrofit the evidence in a highly deceptive, dishonest way,” Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with fellow contrarians, {like|